tbuckley/cabot-search huggingface dataset:
Cell-surface vimentin positive circulating tumor cells as a diagnostic and prognostic indicator in pediatric sarcoma patients.
Authors: Long Dao, Dristhi Ragoonanan, Jessica Foglesong, Izhar Singh Batth, Wafik Tharwat Zaky, Jonathan Benjamin Gill, Diane D. Liu, Aisha Albert, Nancy Beatriz Gordon, Winston W. Huh, Douglas James Harrison, Cynthia E. Herzog, Eugenie Kleinerman, Richard Greg Gorlick, Najat C. Daw, Shulin Li
Journal: Journal of Clinical Oncology (2021)

e15022 Background: Despite advances in care, the 5 year overall survival for patients with relapsed and or metastatic sarcoma remains as low as &lt; 35%. Currently, there are no biomarkers available to assess disease status in patients with sarcomas and as such, disease surveillance remains only reliant on serial imaging which increases the risk of secondary malignancies and heightens patient anxiety. Methods: Here, we enumerated the cell surface vimentin (CSV+) CTCs in the blood of 92 sarcoma pediatric and adolescent and young adult (AYA) patients. Results: We discovered the CSV+CTC could serve as a possible biomarker of disease with sensitivity of 85.3% and specificity of 75%. Significantly, patients who were deemed to be CSV+ CTC positive were found to have a worse overall survival compared to those who were CSV+ CTC negative (773 days vs 2622 days). Addition of readily available genetic analyses improved the sensitivity in both diagnostic and prognostic tests. Conclusions: Our findings indicate that CSV+ CTCs have both diagnostic and prognostic value and can possibly serve as a measure of disease burden.
Development of the Comprehensive Pain Assessment Tool Short Form for Chronic Pancreatitis: Validity and Reliability Testing
Authors: Louise Kuhlmann, Keith Teo, Søren Schou Olesen, Anna Edwards Phillips, Mahya Faghih, Natalie Tuck, Elham Afghani, Vikesh K. Singh, Dhiraj Yadav, John A. Windsor, Asbjørn Mohr Drewes
Journal: Clinical Gastroenterology and Hepatology (2021)

Pain is the foremost complication to chronic pancreatitis (CP), but no validated questionnaires for assessment exist. The COMPAT questionnaire includes all relevant pain dimensions in CP, but a short form is needed to make it usable in clinical practice.The full COMPAT questionnaire was completed by 91 patients and systematically reduced to 6 questions. Pain severity and analgesic use were merged, leaving 5 pain dimensions. The pain dimension ratings were normalized to a 0-100 scale, and the weighted total score was calculated, where 3 dimensions were weighted double. Reliability of the short form was tested in a test-retest study in 76 patients, and concurrent validity tested against the Brief Pain Inventory and Izbicki pain questionnaire. Convergent validity was verified using confirmatory factor analysis, and criterion validity tested against quality-of-life and hospitalization rates.The COMPAT-SF questionnaire consisted of the following pain dimensions: a) pain severity, b) pain pattern, c) factors provoking pain, d) widespread pain, and e) a qualitative pain-describing dimension. Quality of life correlated with the total score and all pain dimensions (P <.05). The total score, pain severity, pain pattern, and factors provoking pain were correlated with hospitalization rates (P <.05). The total score correlated with the Izbicki and Brief Pain Inventory scores (P <.0001). The reliability of the questionnaire in patients in a stable phase was good with an interclass correlation coefficient of 0.89.The COMPAT-SF questionnaire includes the most relevant aspects of pain in CP and is a feasible, reliable, and valid pain assessment instrument recommended to be used in future trials.
Improved esophageal squamous cell carcinoma screening effectiveness by risk‐stratified endoscopic screening: evidence from high‐risk areas in China
Authors: He Li, Chao Ding, Hongmei Zeng, Rongshou Zheng, Maomao Cao, Jiansong Ren, Jufang Shi, Dianqin Sun, Siyi He, Zhixun Yang, Yiwen Yu, Zhe Zhang, Xibin Sun, Guizhou Guo, Guohui Song, Wenqiang Wei, Wanqing Chen, Jie He
Journal: Cancer Communications (2021)

Abstract Background Risk‐stratified endoscopic screening (RSES), which offers endoscopy to those with a high risk of esophageal cancer, has the potential to increase effectiveness and reduce endoscopic demands compared with the universal screening strategy (i.e., endoscopic screening for all targets without risk prediction). Evidence of RSES in high‐risk areas of China is limited. This study aimed to estimate whether RSES based on a 22‐score esophageal squamous cell carcinoma (ESCC) risk prediction model could optimize the universal endoscopic screening strategy for ESCC screening in high‐risk areas of China. Methods Eight epidemiological variables in the ESCC risk prediction model were collected retrospectively from 26,618 individuals aged 40‐69 from three high‐risk areas of China who underwent endoscopic screening between May 2015 and July 2017. The model's performance was estimated using the area under the curve (AUC). Participants were categorized into a high‐risk group and a low‐risk group with a cutoff score having sensitivities of both ESCC and severe dysplasia and above (SDA) at more than 90.0%. Results The ESCC risk prediction model had an AUC of 0.80 (95% confidence interval: 0.75–0.84) in this external population. We found that a score of 8 (ranging from 0 to 22) had a sensitivity of 94.2% for ESCC and 92.5% for SDA. The RSES strategy using this threshold score would allow 50.6% of endoscopies to be avoided and save approximately US$ 0.59 million compared to universal endoscopic screening among 26,618 participants. In addition, a higher prevalence of SDA (1.7% vs. 0.9%), a lower number need to screen (60 vs. 111), and a lower average cost per detected SDA (US$ 3.22 thousand vs. US$ 5.45 thousand) could have been obtained by the RSES strategy. Conclusions The RSES strategy based on individual risk has the potential to optimize the universal endoscopic screening strategy in ESCC high‐risk areas of China.
Correlation of SOX-2 and NOTCH1 copy numbers with vimentin expression in orthotopic patient-derived xenografts of cardioesophageal cancer in immunodeficient mice.
Authors: Anna S. Goncharova, Evgeniy N. Kolesnikov, Ekaterina V. Zaikina, A. V. Volkova, M. V. Mindar, D. V. Khodakova, Ekaterina A. Lukbanova, L. Z. Kurbanova, Mikhail A. Kozhushko, Aleksandr E. Anisimov, Roman E. Myagkov, Sergey V. Sanamyants, Tanzila B. Katsieva
Journal: Journal of Clinical Oncology (2021)

e15034 Background: Cardioesophageal cancer is one of the most common tumors affecting the mucosa of the cardiac stomach and distal esophagus. Despite the variety of treatment strategies and chemotherapy agents, the prognosis for the patients remains poor. The purpose of the study was to analyze the relative copy numbers of SOX-2 and NOTCH1 and vimentin expression in orthotopic patient-derived xenografts of cardioesophageal cancer. Methods: The model of cardioesophageal cancer was created in Balb/c Nude mice with surgical bioptates of moderately differentiated adenocarcinoma obtained from a donor with infiltrative ulcerative cancer of the lower third of the esophagus with a transition to the cardiac stomach into the distal esophagus of Balb/c Nude mice. The index of proliferative activity in the bioptates was assessed by IHC. The relative copy numbers of SOX-2 and NOTCH1 and vimentin expression were determined by Real-Time qPCR. Results: Expression of vimentin was absent in tissues of the donor tumor. The levels of vimentin expression statistically significantly increased in xenografts (1+ and 3+). The SOX-2 and NOTCH1 relative copy numbers were statistically significantly increased in tissues of the donor tumor (0.9 and 0.7), compared to xenografts (1.5±0.03 and 1.7±0.03). Molecular genetic analysis demonstrated an association between an increased vimentin expression and changes in the relative copy numbers of SOX-2 and NOTCH1 (p = 0.013 and p = 0.0001). Conclusions: The relative copy numbers of SOX-2 and NOTCH1 genetic loci was associated with increased expression of the epithelial-mesenchymal transition marker vimentin in tumor tissue samples and changed with each new generation of orthotopic xenografts.
Supporting the Imperfect Use of Amplified Pain Syndrome—Reply
Authors: Asaf Weisman, John Quintner, Youssef Masharawi
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Outcomes of patients with malignancy admitted to the intensive care units (ICU): A prospective study.
Authors: Hazem Assi, Ibrahim Alameh, Maroun Bou Zerdan, Maya Charafeddine, Jessica Khoury, Clara El Nakib, Pierre Bou Khalil
Journal: Journal of Clinical Oncology (2021)

e24001 Background: An important aspect of improving outcomes for patients with malignancy is the provision of critical care during periods of acute deterioration. Decisions regarding whether advanced cancer patients should be admitted to the ICU is based on a complex suite of considerations, including short- and long-term prognosis, quality of life, and therapeutic options to treat cancer. We set to describe demographic, clinical, and survival data and to identify factors associated with short- and long-term mortality in critically ill advanced cancer patients with non-elective admissions to general ICUs. Methods: Critically ill adult (≥18-year-old) cancer patients non-electively admitted to the intensive care units at the American University of Beirut Medical Center (AUBMC) between August 1st, 2015, and March 1st, 2019, were included. Demographic, clinical, and laboratory data was prospectively collected from first day of ICU admission up to 30 days after discharge. This study was strictly observational and clinical decisions were left to the discretion of the ICU team and attending physician. Results: Two hundred seventy-two patients were enrolled in the study between August 1st, 2015, and March 31st, 2019, with an ICU mortality rate of 43.4%, with the number rising to 59% within 30 days of ICU discharge. Mean length of stay in our ICU was 14 days with an interquartile range of 1 to 120 days with a median overall survival of 22 days since date of ICU admission. The major reasons for unplanned ICU admission were sepsis/septic shock (54%) and respiratory failure (33.1%). COX regression analysis showed that sepsis, uncontrolled malignancy, ARDS, multi-organ failure, use of vasopressors, use of mechanical ventilation are major predictors of poor prognosis. Direct admission from the ED was associated with a higher risk of mortality (48.9%) than being transferred from the floor (32.6%) (p = 0.014). Additionally, mortality in patients with solid malignancies (47.6%) was higher than those with hematologic malignancies (34.1%) (p = 0.0048). Conclusions: Patients admitted to the ICU in a tertiary care center in the MENA region are at high risk for short term mortality.
Abstract 10835: Gene Interaction Network Analysis of Cardiac Function in H19 Knockout Mice Fed a High-Fat Diet
Authors: Lijian Cheng, Su Pan, Richard Dixon, Qi Liu
Journal: Circulation (2018)

Introduction: H19 belongs to the imprinted gene network and encodes a long-noncoding RNA (lncRNA). Although recent studies have linked aberrant expression of lncRNAs to cardiovascular disease (CVD)...
Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis.
Authors: Robin Park, Laércio Lopes da Silva, Sunggon Lee, Anwaar Saeed
Journal: Journal of Clinical Oncology (2021)

3557 Background: Mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC) defines a molecular subtype with distinct clinicopathologic characteristics including an excellent response to immunotherapy. Although BRAF mutations are established as a negative prognostic marker in CRC, whether they retain their negative prognostic impact in or alter the response to immunotherapy in dMMR/MSI-H CRC remains unknown. Herein, we present a systematic review and meta-analysis of the impact of BRAF mutations on the overall survival (OS) and immune checkpoint inhibitor (ICI) response in dMMR/MSI-H CRC. Methods: Studies published from inception to 26 January 2021 were searched in PubMed, Embase, and major conference proceedings (AACR, ASCO, and ESMO). Eligible studies included the following: 1) observational studies reporting outcomes based on BRAF mutation status in dMMR/MSI-H CRC patients and 2) experimental studies of ICI reporting outcomes based on BRAF mutation status in dMMR/MSI-H CRC patients. A summary hazard ratio (HR) was calculated for OS in BRAF mutated ( BRAFmut) vs. BRAF wild type ( BRAFwt) patients (pts) with the random effects meta-analysis (REM). A summary odds ratio (OR) was calculated for objective response rate (ORR) in BRAFmut vs. BRAFwt pts treated with ICI with the REM. Results: Database search conducted according to PRISMA guidelines found 4221 studies in total. Initial screening identified 30 studies and after full-text review, 9 studies (N = 4158 pts) were included for the meta-analysis of prognosis (analysis A) and 3 studies (N = 178 pts) were included for the meta-analysis of ICI response (analysis B). The outcome measures are summarized in the table below. Analysis A showed that in stage I-IV dMMR/MSI-H CRC pts, BRAFmut was associated with worse OS than BRAFwt (HR 1.57, 1.23-1.99). The heterogeneity was low (I 2 = 21%). Subgroup analysis showed no significant difference in the prognostic impact of BRAF mutation status between stage IV only and stage I-IV CRC pts. Analysis B showed no difference in ORR (OR 1.04, 0.48-2.25) between BRAFmut vs. BRAFwt dMMR/MSI-H pts who received ICI. The heterogeneity was low (I 2 = 0%). Conclusions: BRAF mutations retain their negative prognostic impact in dMMR/MSI-H stage I-IV and stage IV CRC but are not associated with differential ICI response. Limitations include the following: analysis A was based on retrospective studies; also, the impact of BRAF status on the survival outcome of ICI could not be assessed due to limited number of studies.[Table: see text]
Prognostic Value of Coronary Artery Calcium in Symptomatic Young Individuals Age 18 to 45 Years
Authors: Martin Bødtker Mortensen, Omar Dzaye, Flemming Hald Steffensen, Hans Erik Bøtker, Jesper Møller Jensen, Michael Maeng, Henrik Toft Sørensen, Ron Blankstein, Michael J. Blaha, Bjarne Linde Nørgaard
Journal: Journal of the American College of Cardiology (2021)
Patient preferences for cancer survivorship care: Results of an online survey.
Authors: Deanna J. Attai, Matthew S. Katz, Elani Streja, Jui-Ting Hsiung, Beverly A Zavaleta, Larissa Nekhlyudov
Journal: Journal of Clinical Oncology (2021)

12064 Background: Nearly 17 million cancer survivors live in the United States. Workforce shortages are projected to diminish the number of available medical oncologists (MOs) to care for newly diagnosed patients with cancer and for the growing number of cancer survivors. Models of survivorship care include oncologist-led, primary care-led, and shared care approaches. Recent proposals recommend a risk-stratified approach to care, guided by individual and cancer-specific factors, but there is little evidence regarding patient preferences for non-oncologist survivorship care. Methods: We developed a survey in partnership with patient advocates. The primary endpoints were patient-reported comfort with survivorship care by a primary care provider (PCP) or in a dedicated survivorship clinic. We distributed the survey to online, cancer-specific patient communities from June to August 2020. Logistic regression analyses were adjusted for patient age, race and ethnicity, insurance, and cancer type and stage. Results: Of 1166 responses, 975 surveys were complete and available for analysis. Respondents were primarily women (91%), white (92%), and US residents (73%); 78% had a college or graduate degree. Two-thirds had private insurance. Thirty-six different cancer types were reported; 61% of respondents had breast cancer, and 25% were treated for more than one type of cancer. Most respondents (83%) had nonmetastatic disease, 74% reported experiencing late effects of cancer therapy, and almost all (93%) had a PCP. Only 21% of respondents were comfortable seeing a PCP (versus MO) for survivorship care, including cancer follow-up, side effect management, and monitoring for recurrence or progression. About half (55%) were comfortable with follow-up in a survivorship clinic instead of with their MO. Multivariable analyses showed no significant associations between age, race or ethnicity, insurance, cancer type, or stage at diagnosis and comfort with follow-up care from a PCP or in a survivorship clinic. In analyses restricted to the 439 respondents with a history of early-stage breast cancer, the 239 (54%) who were within 1 to 5 years of diagnosis were less comfortable with PCP versus MO follow-up, compared with the 52 (12%) who were &gt; 15 years from diagnosis (OR 0.40; 95% CI 0.20–0.75; p= 0.004). In this sub-analysis, time from diagnosis was not associated with comfort being seen in a survivorship clinic. Conclusions: In our study, most patients with a history of cancer were not comfortable receiving follow-up care from their PCP. It is often recommended that survivors of early-stage breast cancer transition to primary care for follow-up and surveillance, but our study revealed comfort with this approach only many years after diagnosis. While both PCP survivorship training and patient confidence in PCP follow up is needed, preferences of cancer survivors should be considered in designing new models of survivorship care.
Abstract 838: Ablation of AngiotensinIV Receptor Attenuates Hypofibrinolysis in Acute and Chronic Thrombosis Models via Plasminogen Activator type 1 (PAI-1) Down Regulation.
Authors: Yasushi Numaguchi, Masakazu Ishii, Ryuji Kubota, Xiuyang Ma, Chinatsu Hattori, Shigehiko Mizutani, Toyoaki Murohara
Journal: Circulation (2006)

Reduced fibrinolytic activity is associated with adverse cardiovascular events. Although Insulin-Regulated Aminopepeidase (IRAP) was recently identified as angiotensin (Ang) IV receptor (AT4R), the...
PTU-035 Outcomes of endoscopic resections of large non-polypoid lesions in inflammatory bowel disease: a single united kingdom centre experience
Authors: S Gulati, A Emmanuel, M Burt, P Dubois, B Hayee, A Haji
Journal: Gut (2017)

Introduction  The SCENIC consensus statement recommends endoscopic resection of all visible dysplasia1. Due to technical challenges and limited experience in the West of large colitis associated non-polypoid endoscopic resections, such patients are often subjected to colectomy.   The King’s Institute of Therapeutic Endoscopy (KITE) is a tertiary centre for endoscopic assessment and resection of large/challenging colorectal polyps. Here we present the largest single centre case series of large non-polypoid resections associated with colitis.  Method  Data including demographics, clinical history, lesion characteristics, method of resection and post-resection surveillance were collected prospectively in patients with visible lesions associated with colitis from January 2011 to November 2016. Resection techniques included endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) and hybrid ESD. Surveillance of resection site with magnification chromendoscopy (mCE) was performed at 3 months and pan colonic mCE at 1 year post resection and annually thereafter.  Results  Thirteen lesions satisfied the inclusion criteria in 13 patients. Mean lesion size was 47.3+/-22.4 (20–90) mm. All lesions were non polypoid with distinct margins and no ulceration (Fig.1). High frequency mini-probe ultrasound confirmed intramucosal lesions in 5 cases where pit/vascular pattern was distorted due to inflammation. En bloc resection was achieved in 6 cases. 69% lesions were deeply scarred of which 66% had experienced prior instrumentation. Resection of a single lesion was abandoned due to intense fibrosis. Macroscopic evidence of complete resection was achieved in all remaining cases. Endoscopic diagnosis of pre-cancerous lesions of less than 1000 µm submucosal invasion was confirmed histopathologically in 100% of resected lesions. A single case of small perforation and another with delayed minor bleeding were both managed endoscopically. Mortality/hospital admission within 30 days post resection was 0%. Median follow up was 28 months (12-35) with no recurrence. Alternative site dysplasia was detected in n=2. All lesions were sub 20 mm and resected endoscopically. Two patients were referred for colectomy due to a concomitant diagnosis of neuroendocrine tumour and the second with alternate site advanced dysplasia.  Conclusion  This cohort series demonstrates that endoscopic resection of large non-polypoid lesions in association with colitis is feasible using an array of resection methods, safe and has good long term outcomes in a western tertiary endoscopic centre.  Reference  . Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015;81(3):489–501  Disclosure of Interest  None Declared